Literature DB >> 2503027

Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia.

E M Leonard1, E Raefsky, P Griffith, J Kimball, A W Nienhuis, N S Young.   

Abstract

We treated 22 patients with severe aplastic anaemia refractory to antithymocyte globulin (ATG) with cyclosporine, alone or in combination with prednisone. Eight patients showed significant clinical improvement, all but one to transfusion-independence. Although cyclosporine alone was effective, the addition of prednisone resulted in prompter and fuller haematologic improvement. No patient with an absolute granulocyte count less than 0.2 x 10(9)/l responded to treatment. Haematologic remissions were sustained beyond the treatment period. Of nine patients with Diamond-Blackfan syndrome, one showed a complete response to two separate courses of cyclosporine and relapse with withdrawal of therapy, and a second achieved significant reduction in corticosteroid dose without relapse; however, seven cases failed to respond. Two of three adults with acquired pure red cell aplasia recovered. A combination of cyclosporine and corticosteroids may be effective therapy in patients with aplastic anaemia who have failed ATG treatment. Occasional cases of congenital and acquired pure red cell aplasia may also respond to cyclosporine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503027     DOI: 10.1111/j.1365-2141.1989.tb07695.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  21 in total

Review 1.  Aplastic anaemia: continued cause for concern.

Authors:  D K Webb
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

2.  Clinical observation on treatment of chronic aplastic anemia by Shengxuening and cyclosporin A.

Authors:  Xue-zhong Zhang; Yan-li Xu; Juan Jin; Xiu-qun Zhang; Lei Zhang; Ai-ling Su
Journal:  Chin J Integr Med       Date:  2006-06       Impact factor: 1.978

3.  Cyclosporin A in aplastic anemia--report of a workshop.

Authors:  H Schrezenmeier; M Schlander; A Raghavachar
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

4.  Antithymocyte globulin induced recurrent seizures in a case of severe aplastic anemia.

Authors:  Sanjeev Kumar Sharma; Pawan Kumar Singh; Tulika Seth; Pravas Mishra; Manoranjan Mahapatra
Journal:  Indian J Hematol Blood Transfus       Date:  2012-08-21       Impact factor: 0.900

5.  Clinical features, mutations and treatment of 104 patients of Diamond-Blackfan anemia in China: a single-center retrospective study.

Authors:  Yang Wan; Xiaojuan Chen; Wenbin An; Min Ruan; Jingliao Zhang; Lixian Chang; Ranran Zhang; Shuai Zhu; Yingchi Zhang; Wenyu Yang; Ye Guo; Weiping Yuan; Yao Zou; Yumei Chen; Xiaofan Zhu
Journal:  Int J Hematol       Date:  2016-06-21       Impact factor: 2.490

6.  Outcome of a novel immunosuppressive strategy of cyclosporine, levamisole and danazol for severe aplastic anemia.

Authors:  Min Wang; Xingxin Li; Jun Shi; Yingqi Shao; Meili Ge; Jinbo Huang; Zhendong Huang; Jing Zhang; Neng Nie; Yizhou Zheng
Journal:  Int J Hematol       Date:  2015-06-14       Impact factor: 2.490

Review 7.  How I treat Diamond-Blackfan anemia.

Authors:  Adrianna Vlachos; Ellen Muir
Journal:  Blood       Date:  2010-07-22       Impact factor: 22.113

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  Cyclosporine therapy for acquired aplastic anemia: predictive factors for the response and long-term prognosis.

Authors:  Hirohito Yamazaki; Chiharu Sugimori; Tatsuya Chuhjo; Shinji Nakao
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

10.  Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A.

Authors:  Toshiki Yamada; Hisashi Tsurumi; Senji Kasahara; Takeshi Hara; Michio Sawada; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-10       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.